1. Home
  2. SNT vs ONCY Comparison

SNT vs ONCY Comparison

Compare SNT & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Senstar Technologies Ltd.

SNT

Senstar Technologies Ltd.

HOLD

Current Price

$2.96

Market Cap

87.5M

ML Signal

HOLD

Logo Oncolytics Biotech Inc.

ONCY

Oncolytics Biotech Inc.

HOLD

Current Price

$0.85

Market Cap

94.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNT
ONCY
Founded
1965
1998
Country
Canada
Canada
Employees
N/A
N/A
Industry
Telecommunications Equipment
Pharmaceuticals and Biotechnology
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
87.5M
94.0M
IPO Year
2023
2002

Fundamental Metrics

Financial Performance
Metric
SNT
ONCY
Price
$2.96
$0.85
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.33
AVG Volume (30 Days)
17.9K
822.9K
Earning Date
04-22-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.57
$0.33
52 Week High
$5.34
$1.51

Technical Indicators

Market Signals
Indicator
SNT
ONCY
Relative Strength Index (RSI) 29.41 36.07
Support Level $2.75 $0.79
Resistance Level $4.54 $1.08
Average True Range (ATR) 0.16 0.05
MACD 0.01 -0.02
Stochastic Oscillator 3.82 14.50

Price Performance

Historical Comparison
SNT
ONCY

About SNT Senstar Technologies Ltd.

Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.

About ONCY Oncolytics Biotech Inc.

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.

Share on Social Networks: